Epstein D H, Preston K L
Clinical Pharmacology and Therapeutics Branch, Treatment Section, National Institute on Drug Abuse/Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.
Addiction. 2003 Mar;98(3):269-79. doi: 10.1046/j.1360-0443.2003.00310.x.
To determine whether cannabinoid-positive urine specimens in heroin-dependent out-patients predict other drug use or impairments in psychosocial functioning, and whether such outcomes are better predicted by cannabis-use disorders than by cannabis use itself.
Retrospective analyses of three clinical trials; each included a behavioral intervention (contingency management) for cocaine or heroin use during methadone maintenance. Trials lasted 25-29 weeks; follow-up evaluations occurred 3, 6 and 12 months post-treatment. For the present analyses, data were pooled across trials where appropriate.
Urban out-patient methadone clinic.
Four hundred and eight polydrug abusers meeting methadone-maintenance criteria.
Participants were categorized as non-users, occasional users or frequent users of cannabis based on thrice-weekly qualitative urinalyses. Cannabis-use disorders were assessed with the Diagnostic Interview Schedule III-R. Outcome measures included proportion of cocaine- and opiate-positive urines and the Addiction Severity Index (at intake and follow-ups).
Cannabis use was not associated with retention, use of cocaine or heroin, or any other outcome measure during or after treatment. Our analyses had a power of 0.95 to detect an r2 of 0.11 between cannabis use and heroin or cocaine use; the r2 we detected was less than 0.03 and non-significant. A previous finding, that cannabis use predicted lapse to heroin use in heroin-abstinent patients, did not replicate in our sample. However, cannabis-use disorders were associated weakly with psychosocial problems at post-treatment follow-up.
Cannabinoid-positive urines need not be a major focus of clinical attention during treatment for opiate dependence, unless patients report symptoms of cannabis-use disorders.
确定海洛因依赖门诊患者中大麻素阳性尿液样本是否能预测其他药物使用情况或心理社会功能受损情况,以及大麻使用障碍对这些结果的预测是否优于大麻使用本身。
对三项临床试验进行回顾性分析;每项试验都包括在美沙酮维持治疗期间针对可卡因或海洛因使用的行为干预(应急管理)。试验持续25 - 29周;治疗后3、6和12个月进行随访评估。在适当情况下,将各试验的数据合并用于本分析。
城市门诊美沙酮诊所。
408名符合美沙酮维持治疗标准的多药滥用者。
根据每周三次的定性尿液分析,将参与者分为大麻非使用者、偶尔使用者或频繁使用者。使用诊断访谈表III - R评估大麻使用障碍。结果指标包括可卡因和阿片类药物阳性尿液的比例以及成瘾严重程度指数(在入组时和随访时)。
大麻使用与治疗期间或治疗后是否继续治疗、可卡因或海洛因的使用或任何其他结果指标均无关联。我们的分析有95%的把握度检测到大麻使用与海洛因或可卡因使用之间的r2为0.11;我们检测到的r2小于0.03且无统计学意义。先前的一项研究发现,大麻使用可预测海洛因戒断患者复吸海洛因,但在我们的样本中未得到重复验证。然而,大麻使用障碍与治疗后随访时的心理社会问题存在弱关联。
在阿片类药物依赖治疗期间,除非患者报告有大麻使用障碍的症状,否则大麻素阳性尿液不必成为临床关注的主要焦点。